Drug intelligence / Profile preview

Turmicon 95

Development stage: Unknown
Lead developer: Epicon Lifesciences
Administration: Oral

Overview

Turmicon 95 is a nutraceutical dietary supplement developed and marketed by Epicon Lifesciences. It is categorized as an herbal immunity booster and is likely a standardized turmeric extract containing 95% curcuminoids. Curcumin, the active constituent, exhibits potent anti-inflammatory and antioxidant properties by modulating various molecular targets, including the inhibition of NF-kappaB and cyclooxygenase-2 (COX-2). The product is intended for oral consumption to support immune function and general wellness.

Brand names: Turmicon 95Turmicon95Turmicon-95
Other names: Turmicon 95Turmicon95Turmicon-95

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Turmicon 95.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Turmicon 95.

Explore the full profile